Indian Markets Face Flat Opening as Major Companies Release Quarterly Earnings

Indian stock markets are heading for a flat start today, with the GIFT Nifty pointing to a subdued opening for the Sensex and Nifty. The GIFT Nifty traded near the 25,213 mark, up by roughly 12 points or 0.05 percent from the previous close.

Market Gains

Domestic equity benchmarks extended their winning streak for a second straight session. The 30-share Sensex rallied 773 points to finish at its highest level in nearly nine months, closing at 81,879.40. During the day, the index jumped over 1,400 points to touch an intraday high of 82,520.40. The Nifty 50 advanced 210 points to close above the 25,250 mark at 25,255.05.

Corporate Earnings

Numerous companies are drawing attention as they report their second-quarter financial results for fiscal year 2027. Tata Power reported a 48.6 percent year-on-year growth in consolidated net profit, reaching 1,366 crore rupees compared to 919 crore rupees in the same period last year. Cupid saw its consolidated net profit more than double to 56.2 crore rupees, while its operating revenue climbed sharply to 188 crore rupees. Garden Reach Shipbuilders and Engineers posted a 12 percent rise in net profit to 171.97 crore rupees. Mishra Dhatu Nigam recorded a greater than twofold jump in net profit to 28 crore rupees, whereas Triveni Turbine suffered a 41.6 percent drop in net profit down to 53.3 crore rupees.

Stock Actions

Beyond earnings reports, several corporate updates are in play. ITC increased the price of its Gold Flake RSFT cigarette pack by 10 rupees to reach 135 rupees. Bajaj Finance launched its qualified institutional placement of equity shares with a floor price of 992.25 rupees per share. Meanwhile, the US Food and Drug Administration classified an inspection of Aurobindo Pharma's Lannett facility as Official Action Indicated.

Context

Stock markets frequently react to quarterly corporate financial results and major regulatory updates as investors adjust their portfolios based on company performance. Share prices often shift in response to sudden changes in net profit, product pricing, and regulatory inspections by agencies like the US FDA.